U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C33H40N2O9
Molecular Weight 608.68
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RESERPINE

SMILES

COc1ccc2c3CCN4C[C@@]5([H])C[C@]([H])([C@@]([H])([C@]([H])([C@@]5([H])C[C@]4([H])c3[nH]c2c1)C(=O)OC)OC)OC(=O)c6cc(c(c(c6)OC)OC)OC

InChI

InChIKey=QEVHRUUCFGRFIF-MDEJGZGSSA-N
InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1

HIDE SMILES / InChI

Molecular Formula C33H40N2O9
Molecular Weight 608.68
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Reserpine is an alkaloid, isolated from the Rauwolfia serpentina plant and developed by Ciba pharma. Reserpine was approved by FDA for the treatment of hypertension and psychotic disorders. The drug exerts its effect by blocking two vesicular monoamine transporters, VMAT1 and VMAT2. The blockade results in vesicles that lose their ability to store neurotransmitter molecules. Neurotransmitters, thus retained in cytosol, are then neutralized by MAO.

Originator

Curator's Comment:: Later Ciba-Geigy and now Novartis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
160.0 nM [IC50]
350.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RESERPINE

Approved Use

Mild essential hypertension; also useful as adjunctive therapy with other antihypertensive agents in the more severe forms of hypertension; relief of symptoms in agitated psychotic states (e.g., schizophrenia), primarily in those individuals unable to tolerate phenothiazine derivatives or in those who also require antihypertensive medication.

Launch Date

-4.66300797E11
Palliative
RESERPINE

Approved Use

Mild essential hypertension; also useful as adjunctive therapy with other antihypertensive agents in the more severe forms of hypertension; relief of symptoms in agitated psychotic states (e.g., schizophrenia), primarily in those individuals unable to tolerate phenothiazine derivatives or in those who also require antihypertensive medication.

Launch Date

-4.66300797E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.2 ng/mL
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RESERPINE plasma
Equus caballus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.8 ng × h/mL
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RESERPINE plasma
Equus caballus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
23.6 h
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RESERPINE plasma
Equus caballus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
Disc. AE: Drowsiness, Light headedness...
AEs leading to
discontinuation/dose reduction:
Drowsiness (1 patient)
Light headedness (light, 1 patient)
Sources:
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
Disc. AE: Upper abdominal pain, Postural hypotension...
AEs leading to
discontinuation/dose reduction:
Upper abdominal pain (1 patient)
Postural hypotension (1 patient)
Electrocardiogram abnormal (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Drowsiness 1 patient
Disc. AE
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
Light headedness light, 1 patient
Disc. AE
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
Electrocardiogram abnormal 1 patient
Disc. AE
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
Postural hypotension 1 patient
Disc. AE
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
Upper abdominal pain 1 patient
Disc. AE
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [Activation >3.9811 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no
no
unlikely [Inhibition 20 uM]
weak [IC50 133 uM]
weak [IC50 133 uM]
weak [IC50 58 uM]
yes [IC50 2.8 uM]
yes [IC50 20.4 uM]
yes [IC50 26.3 uM]
yes [IC50 <0.03 uM]
yes [IC50 <0.2 uM]
yes [Inhibition 20 uM]
yes [Inhibition 20 uM]
yes [Ki 1.38 uM]
yes [Ki 295 uM]
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Transient global amnesia associated with cardiac arrhythmia and digitalis intoxication.
1975 Sep-Oct
The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved?
1999
Reserpine modulates serotonin transporter mRNA levels in the rat brain.
1999
The role of the sympathetic nervous system in the regulation of leptin synthesis in C57BL/6 mice.
1999 Feb 12
The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat.
2000 Feb
Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys.
2000 Mar
Determination of PAH in food samples by HPLC with fluorimetric detection following sonication extraction without sample clean-up.
2001 Aug
Blood pressure-independent effect of angiotensin AT1 receptor blockade on renal endothelin-1 production in hypertensive uremic rats.
2001 Aug
Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography.
2001 Aug 5
The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice.
2001 Feb 13
Spectrophotometric, septrofluorimetric and LC determination of lisinopril.
2001 Jul
Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease.
2001 Jun
Application of conventional UV, photodiode array (PDA) and fluorescence (FL) detection to analysis of phenolic acids in plant material and pharmaceutical preparations.
2001 Mar
[Study of diphacinone in biological samples by high performance liquid chromatography/diode array detector].
2001 May
Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.
2001 May
Determination of aliphatic amines in water by liquid chromatography using solid-phase extraction cartridges for preconcentration and derivatization.
2001 Oct
[Determination of nitidine in different parts of Zanthoxylum nitidum].
2001 Sep
[Determination of ofloxacin in human fallopian tube, uterus and serum by high performance liquid chromatography].
2002 Feb
Increase of free cysteine and citric acid in plant cells exposed to cobalt ions.
2002 Jul
A modified HPLC method for the determination of ochratoxin A by fluorescence detection.
2002 Oct
Determination of peptides and amino acids from wool and beer with sensitive fluorescent reagent 2-(9-carbazole)-ethyl chloroformate by reverse phase high-performance liquid chromotography and liquid chromotography mass spectrometry.
2003 Feb 1
DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells.
2003 Feb 24
Analysis of selected withanolides in plant extract by capillary electrochromatography and microemulsion electrokinetic chromatography.
2003 Jan
Growth-inhibitory effects of the chemopreventive agent indole-3-carbinol are increased in combination with the polyamine putrescine in the SW480 colon tumour cell line.
2003 Jan 14
Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.
2003 Jun
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
2003 May 21
Patents

Sample Use Guides

Hypertension: In the average patient not receiving other antihypertensive agents, the usual initial dosage is 0.5 mg daily for 1 or 2 weeks. For maintenance, reduce to 0.1-0.25 mg daily. Psychiatric Disorders: the usual initial dosage is 0.5 mg daily, but may range from 0.1 mg to 1.0 mg. Adjust dosage upward or downward according to the patient's response.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:57:12 UTC 2021
Edited
by admin
on Fri Jun 25 20:57:12 UTC 2021
Record UNII
8B1QWR724A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RESERPINE
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
RESERPINE COMPONENT OF CAM-AP-ES
Common Name English
HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE COMPONENT RESERPINE
Common Name English
YOHIMBAN-16-CARBOXYLIC ACID, 11,17-DIMETHOXY-18-((3,4,5-TRIMETHOXYBENZOYL)OXY)-, METHYL ESTER, (3.BETA.,16.BETA.,17.ALPHA.,18.BETA.,20.ALPHA.)-
Common Name English
SERPASIL
Brand Name English
HYDRAP-ES COMPONENT RESERPINE
Common Name English
RESERPINE COMPONENT OF SER-A-GEN
Common Name English
RESERPINE [WHO-IP]
Common Name English
METATENSIN COMPONENT RESERPINE
Common Name English
RESERPINE [JAN]
Common Name English
ENT-50146
Code English
RESERPINE COMPONENT OF HYDROMOX R
Common Name English
SANDRIL
Brand Name English
RESERPINE [MI]
Common Name English
REGROTON COMPONENT RESERPINE
Common Name English
CAM-AP-ES COMPONENT RESERPINE
Common Name English
RESERPINE [USP MONOGRAPH]
Common Name English
DIUTENSEN-R COMPONENT RESERPINE
Common Name English
RESERPINE [ORANGE BOOK]
Common Name English
SER-A-GEN COMPONENT RESERPINE
Common Name English
RESERPINE COMPONENT OF HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE
Common Name English
RESERPINE [EP MONOGRAPH]
Common Name English
RESERPINE COMPONENT OF SALUTENSIN
Common Name English
RESERPINE [MART.]
Common Name English
RESERPINE COMPONENT OF DIUTENSEN-R
Common Name English
HYDROSERPINE PLUS (R-H-H) COMPONENT RESERPINE
Common Name English
RAU-SED
Brand Name English
RESERPINE [HSDB]
Common Name English
NSC-237659
Code English
RESERPINE COMPONENT OF DRALSERP
Common Name English
RESERPINE [WHO-DD]
Common Name English
RESERPINE COMPONENT OF METATENSIN
Common Name English
RESERPINE COMPONENT OF HYDROPRES
Common Name English
RESERPINUM [WHO-IP LATIN]
Common Name English
RENESE-R COMPONENT RESERPINE
Common Name English
RESERPINE COMPONENT OF SERPASIL-ESIDRIX
Common Name English
RESERPINUM
HPUS   WHO-IP LATIN  
Common Name English
RESERPINE COMPONENT OF RENESE-R
Common Name English
H.R.-50 COMPONENT RESERPINE
Common Name English
RESERPINE COMPONENT OF HYDRO-RESERP
Common Name English
RESERPINE COMPONENT OF REGROTON
Common Name English
RESERPINE COMPONENT OF HYDRAP-ES
Common Name English
RESERPINE [VANDF]
Common Name English
RESERPINE COMPONENT OF DEMI-REGROTON
Common Name English
RESERPINE COMPONENT OF SERPASIL-APRESOLINE
Common Name English
HYDROMOX R COMPONENT RESERPINE
Common Name English
DEMI-REGROTON COMPONENT RESERPINE
Common Name English
SERPASIL-ESIDRIX COMPONENT RESERPINE
Common Name English
RESERPINE [IARC]
Common Name English
RESERPINE COMPONENT OF UNIPRES
Common Name English
RESERPINE COMPONENT OF NAQUIVAL
Common Name English
APOPLON
Brand Name English
RESERPINE [USP-RS]
Common Name English
RESERPINE COMPONENT OF H.R.-50
Common Name English
SERPASIL-APRESOLINE COMPONENT RESERPINE
Common Name English
HYDROPRES COMPONENT RESERPINE
Common Name English
SERPALAN
Brand Name English
HYDRO-RESERP COMPONENT RESERPINE
Common Name English
RESERPINUM [HPUS]
Common Name English
RESERPINE [INN]
Common Name English
SALUTENSIN COMPONENT RESERPINE
Common Name English
RESERPINE COMPONENT OF SER-AP-ES
Common Name English
RESERPINE COMPONENT OF HYDROSERPINE PLUS (R-H-H)
Common Name English
NSC-59272
Code English
DRALSERP COMPONENT RESERPINE
Common Name English
UNIPRES COMPONENT RESERPINE
Common Name English
METHYL 18.BETA.-HYDROXY-11,17.ALPHA.-DIMETHOXY-3.BETA.,20.ALPHA.-YOHIMBAN-16.BETA.-CARBOXYLATE 3,4,5-TRIMETHOXYBENZOATE (ESTER).
Common Name English
NAQUIVAL COMPONENT RESERPINE
Common Name English
METHYL (3.BETA.,16.BETA.,17.ALPHA.,18.BETA.,20.ALPHA.)-11,17-DIMETHOXY-18-((3,4,5-TRIMETHOXYBENZOYL)OXY)YOHIMBAN-16-CARBOXYLATE
Common Name English
SER-AP-ES COMPONENT RESERPINE
Common Name English
Classification Tree Code System Code
WHO-ATC C02LA71
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
NCI_THESAURUS C1744
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
WHO-ATC C02AA52
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
NDF-RT N0000175650
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
WHO-ATC C02LA01
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
NCI_THESAURUS C29747
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
WHO-ATC C02LA51
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
WHO-VATC QC02LA51
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
WHO-ATC C02AA02
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
NDF-RT N0000175640
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
EPA PESTICIDE CODE 123101
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
WHO-VATC QC02AA02
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
WHO-VATC QC02LA01
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
WHO-VATC QC02AA52
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
WHO-VATC QC02LA71
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
LIVERTOX 841
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
IARC Reserpine
Code System Code Type Description
MERCK INDEX
M9535
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY Merck Index
INN
282
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY
DRUG CENTRAL
2370
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY
DRUG BANK
DB00206
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY
PUBCHEM
5770
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY
NCI_THESAURUS
C803
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY
IUPHAR
4823
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY
CAS
50-55-5
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY
USP_CATALOG
1601000
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY USP-RS
WHO INTERNATIONAL PHARMACOPEIA
RESERPINE
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY Description: Small, white to pale beige crystals or a white to pale beige, crystalline powder; odourless. Solubility: Practically insoluble in water; soluble in 90 parts of acetone R; very slightly soluble in methanol R, ethanol (~750 g/l) TS, and ether R. Category: Neuroleptic; hypotensive. Storage: Reserpine should be kept in a well-closed container, protected from light.Additional information: Reserpine darkens slowly on exposure to light, but more rapidly in solution. Definition: Reserpine contains not less than 98.0% and not more than 102.0% of C33H40N2O9, calculated with reference to thedried substance.
FDA UNII
8B1QWR724A
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY
EPA CompTox
50-55-5
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-047-9
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY
EVMPD
SUB10286MIG
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY
HSDB
213
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY
ChEMBL
CHEMBL772
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY
RXCUI
9260
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
RESERPINE
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY
MESH
D012110
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY
LACTMED
Reserpine
Created by admin on Fri Jun 25 20:57:12 UTC 2021 , Edited by admin on Fri Jun 25 20:57:12 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY